Establishing secure connection…Loading editor…Preparing document…

SEC Filing Guardant Health Inc

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Proposal 3 - Proposed Amendment to the Certificate of Incorporation to Authorize Up to 10,000,000 Shares of Preferred Stock

The Board of Directors has unanimously adopted and submitted to the stockholders for approval an amendment to the Certificate of Incorporation (the "Preferred Stock Amendment") to authorize the issuance by the Company of up to 10,000,000 shares of preferred stock (the "Preferred Stock"). The text of the Preferred Stock Amendment is attached hereto as Exhibit C and is incorporated herein by reference.

The Board of Directors believes that the authorization of the Preferred Stock is in the best interests of the Company and its stockholders and believes that it is advisable to authorize such shares and have them available in connection with possible future transactions, such as financings, strategic alliances, corporate mergers, acquisitions, possible funding of new product programs or businesses and other uses not presently determinable and as may be deemed to be feasible and in the best interests of the Company. In addition, the Board of Directors believes that it is desirable that the Company have the flexibility to issue shares of Preferred Stock without further stockholder action, except as otherwise provided by law.

The Preferred Stock will have such designations, preferences, conversion rights, cumulative, relative, participating, optional or other rights, including voting rights, qualifications, limitations or restrictions thereof as are determined by the Board of Directors. Thus, if the Preferred Stock Amendment is approved, the Board of Directors would be entitled to authorize the creation and issuance of up to 10,000,000 shares of Preferred Stock in one or more series with such limitations and restrictions as may be determined in the Board's sole discretion, without further authorization by the Company's stockholders. Stockholders will not have preemptive rights to subscribe for shares of Preferred Stock.

It is not possible to determine the actual effect of the Preferred Stock on the rights of the stockholders of the Company until the Board of Directors determines the rights of the holders of a series of the Preferred Stock. However, such effects might include (i) restrictions on the payment of dividends to holders of the Common Stock; (ii) dilution of voting power to the extent that the holders of shares of Preferred Stock are given voting rights; (iii) dilution of the equity interests and voting power if the Preferred Stock is convertible into Common Stock; and (iv) restrictions upon any distribution of assets to the holders of the Common Stock upon liquidation or dissolution and until the satisfaction of any liquidation preference granted to the holders of Preferred Stock.

The Board of Directors is required by Delaware law to make any determination to issue shares of Preferred Stock based upon its judgment as to the best interests of the stockholders and the Company. Although the Board of Directors has no present intention of doing so, it could issue shares of Preferred Stock (within the limits imposed by applicable law) that could, depending on the terms of such series, make more difficult or discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or other means. When in the judgment of the Board of Directors such action would be in the best interests of the stockholders and the Company, the issuance of shares of Preferred Stock could be used to create voting or other impediments or to discourage persons seeking to gain control of the Company, for example, by the sale of Preferred Stock to purchasers favorable to the Board of Directors. In addition, the Board of Directors could authorize holders of a series of Preferred Stock to vote either separately as a class or with the holders of Common Stock, on any merger, sale or exchange of assets by the Company or any other extraordinary corporate transaction. The existence of the additional authorized shares could have the effect of discouraging unsolicited takeover attempts. The issuance of new shares could also be used to dilute the stock ownership of a person or entity seeking to obtain control of the Company should the Board of Directors consider the action of such entity or person not to be in the best interests of the stockholders and the Company. Such issuance of Preferred Stock could also have the effect of diluting the earnings per share and book value per share of the Common Stock held by the holders of Common Stock.

While the Company may consider effecting an equity offering of Preferred Stock in the future for the purposes of raising additional working capital or otherwise, the Company, as of the date hereof, has no agreements or understandings with any third party to effect any such offering and no assurances are given that any offering will in fact be effected.

Dissenters' Rights

Pursuant to the DGCL, the Company's stockholders are not entitled to dissenters' rights of appraisal with respect to the Preferred Stock Amendment.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE APPROVAL OF THE PREFERRED STOCK AMENDMENT.

Exhibit C

PROPOSED AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ARIAD PHARMACEUTICALS, INC.

Section 4 of the Certificate of Incorporation of the Company shall be amended to read as follows:

"4. Number of Shares. The total number of shares of stock that the Corporation shall have authority to issue is: seventy million (70,000,000), consisting of sixty million (60,000,000) shares of common stock (the "Common Stock") of the par value of one-tenth of one cent ($.001) each and ten million (10,000,000) shares of preferred stock (the "Preferred Stock") of the par value of one cent ($.01) each.

"Designation of Classes; Relative Rights, etc. The designation, relative rights, preferences and limitations of the shares of each class are as follows:

"The shares of Preferred Stock may be issued from time to time in one or more series of any number of shares, provided that the aggregate number of shares issued and not canceled of any and all such series shall not exceed the total number of shares of Preferred Stock hereinabove authorized, and with distinctive serial designations, all as shall hereafter be stated and expressed in the resolution or resolutions providing for the issue of such shares of Preferred Stock from time to time adopted by the Board of Directors pursuant to authority so to do which is hereby vested in the Board of Directors. Each series of shares of Preferred Stock (a) may have such voting powers, full or limited, or may be without voting powers; (b) may be subject to redemption at such time or times and at such prices; (c) may be entitled to receive dividends (which may be cumulative or non-cumulative) at such rate or rates, on such conditions and at such times, and payable in preference to, or in such relation to, the dividends payable on any other class or classes or series of stock; (d) may have such rights upon the dissolution of, or upon any distribution of the assets of, the Corporation; (e) may be made convertible into or exchangeable for, shares of any other class or classes or of any other series of the same or any other class or classes of shares of the Corporation at such price or prices or at such rates of exchange and with such adjustments; (f) may be entitled to the benefit of a sinking fund to be applied to the purchase or redemption of shares of such series in such amount or amounts; (g) may be entitled to the benefit of conditions and restrictions upon the creation of indebtedness of the Corporation or any subsidiary, upon the issue of any additional shares (including additional shares of such series or of any other series) and upon the payment of dividends or the making of other distributions on, and the purchase, redemption or other acquisition by the Corporation or any subsidiary of, any outstanding shares of the Corporation and (h) may have such other relative, participating, optional or other special rights, qualifications, limitations or restrictions thereof, all as shall be stated in said resolution or resolutions providing for the issue of such shares of Preferred Stock. Shares of Preferred Stock of any series that have been redeemed (whether through the operation of a sinking fund or otherwise) or that if convertible or exchangeable, have been converted into or exchanged for shares of any other class or classes shall have the status of authorized and unissued shares of Preferred Stock of the same series and may be reissued as a part of the series of which they were originally a part or may be reclassified and reissued as part of a new series of shares of Preferred Stock to be created by resolution or resolutions of the Board of Directors or as part of any other series of shares of Preferred Stock, all subject to the conditions or restrictions on issuance set forth in the resolution or resolutions adopted by the Board of Directors providing for the issue of any series of shares of Preferred Stock.

"Subject to the provisions of any applicable law or of the By-laws of the Corporation as from time to time amended, with respect to the closing of the transfer books or the fixing of a record date for the determination of stockholders entitled to vote and except as otherwise provided by law or by the resolution or resolutions providing for the issue of any series of shares of Preferred Stock, the holders of outstanding shares of Common Stock shall exclusively possess voting power for the election of directors and for all other purposes, each holder of record of shares of Common Stock being entitled to one vote for each share of Common Stock standing in his or her name on the books of the Corporation. Except as otherwise provided by the resolution or resolutions providing for the issue of any series of shares of Preferred Stock, the holders of shares of Common Stock shall be entitled, to the exclusion of the holders of shares of Preferred Stock of any and all series, to receive such dividends as from time to time may be declared by the Board of Directors. In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, after payment shall have been made to be holders of shares of Preferred Stock of the full amount to which they shall be entitled pursuant to the resolution or resolutions providing for the issue of any series of shares of Preferred Stock, the holders of shares of Common Stock shall be entitled, to the exclusion of the holders of shares of Preferred Stock of any and all series, to share, ratably according to the number of shares of Common Stock held by them, in all remaining assets of the Corporation available for distribution to its stockholders.

"Subject to the provisions of this Certificate of Incorporation and except as otherwise provided by law, the stock of the Corporation, regardless of class, may be issued for such consideration and for such corporate purposes as the Board of Directors may from time to time determine."

Name of Signatory

Date

ARIAD Pharmaceuticals, Inc.

Authorized Signature

Title

Comments / Notes

Enter text✕

What the SEC Filing for Guardant Health Inc Covers

An SEC Filing for Guardant Health Inc refers to the company’s regulatory submissions to the U.S. Securities and Exchange Commission (SEC), including periodic reports (Form 10-K, 10-Q), material event reports (Form 8-K), proxy statements, and registration statements. These filings disclose financial results, risk factors, management discussion, related exhibits, and officer or director certifications. Filings become public records on EDGAR and drive investor transparency, listing compliance, and regulatory oversight. Accurate content, timely signatures, and correct exhibit attachments are essential to meet federal securities law obligations and to avoid enforcement or market consequences.

Why a Complete, Compliant SEC Filing Matters

A correct SEC Filing supports disclosure obligations, preserves investor confidence, and reduces regulatory exposure under the Securities Exchange Act. Timely, accurate filings limit enforcement risk, investor litigation, and trading interruptions while documenting corporate decisions for audit and compliance purposes.

Why a Complete, Compliant SEC Filing Matters

Who Prepares and Reviews Guardant Health Inc SEC Filings

Final sign-off typically rests with authorized officers and corporate counsel before EDGAR submission to the SEC.

  • Corporate legal and compliance teams: Draft disclosures, verify materiality, and confirm legal sufficiency of statements.
  • Investor relations and finance: Provide financial data, MD&A content, and manage public communications.
  • External auditors and counsel: Review financial statements, confirm disclosures, and approve certifications for signature.

Core Elements to Include in a Professional SEC Filing

A professional filing combines formal cover pages, complete financials, required exhibits, authorized signatures, officer certifications, and a clear submission checklist to support EDGAR intake and auditability.

Cover Page

Complete form header with company name, CIK, form type, fiscal period, and issuer status to route the filing correctly.

Financial Statements

Audited or unaudited financial statements with footnotes, schedules, and auditor attestation where required by SEC rules.

Exhibits

Contracts, material agreements, and certifications attached as exhibits; each exhibit must be referenced in the body of the filing.

Officer Certifications

CEO/CFO Sarbanes-Oxley certifications or attestations signed and dated to certify the accuracy of financial reporting.

Authorized Signatures

Corporate officer or authorized agent signatures with printed names, titles, and signature dates matching the document text.

Submission Checklist

EDGAR-compatible file names, exhibit indexes, conversion to acceptable formats, and final verification steps before upload.

Step-by-Step: Preparing and Signing the Filing

Follow a clear sequence from drafting to EDGAR submission to minimize errors and preserve evidence of review and authorization.

  • 01
    Collect Materials: Gather financials, exhibits, board resolutions.
  • 02
    Draft Filing: Complete narrative sections and cross-check citations.
  • 03
    Obtain Signatures: Secure officer signatures and certifications.
  • 04
    Submit EDGAR: Upload validated files and confirm acceptance.

How to Configure an Online Signing Workflow

Set signer order, authentication level, and file format before sending to keep the process auditable and EDGAR-ready.

Field Configuration
Authentication Email link, SMS code, or stronger KBA where required
Signature Type Typed, drawn, or PKI-based digital signature
Routing Order Sequential or parallel signer flow as corporate policy
Retention Store final PDF and audit trail for regulatory recordkeeping

Technical and Integration Considerations for Electronic Signatures

Integrations with document repositories and ERP/CRM systems reduce manual transcription and preserve auditability during regulatory reviews.

  • File Formats: PDF/A and searchable PDF recommended for EDGAR ingestion
  • Integrations: Connect to systems like NetSuite or Salesforce for source data
  • Authentication: Support for email, SMS, or advanced signer verification

Where to File and How Documents Move After Signing

Understand each delivery endpoint and the routing steps that follow signature to ensure compliance and timely disclosure.

  • EDGAR Submission: Final signed PDF uploaded for public filing and indexing
  • Exchange Notices: Notify the listing exchange per listing rules if required
  • Investor Relations Distribution: Post filing materials on corporate investor portal
  • Regulatory Correspondence: Retain copies for SEC staff follow-ups and audits

Typical Deadlines and Timing Expectations

Key filing windows differ by form and issuer status; confirm specific SEC timing and accelerated filer rules before scheduling submission.

Form 8-K:

File within four business days of the triggering event

Form 10-Q:

Deadline varies by filer status; typically 40–45 days after quarter end

Form 10-K:

Deadline varies by filer status; typically 60–90 days after fiscal year end

Registration Statements:

Pre-filing and comment cycles require coordination with counsel

Exchange Notices:

Timing set by exchange rules; act promptly when required

Consequences of Incomplete or Untimely Filings

SEC Enforcement: Civil penalties and oversight actions
Investor Litigation: Increased risk of shareholder suits
Trading Impact: Listing suspensions or trading halts possible
Restatements: Material errors may require public restatement
Reputational Harm: Impaired investor confidence and market perception
Operational Delays: Delayed deals and financing activities

How SEC Forms Differ: 8-K, 10-Q, 10-K, and S-1

Compare the primary purpose and timing of common SEC forms to pick the correct filing type for a corporate event or reporting period.

Document Type Purpose Typical Timing
Form 8-K current event disclosure within 4 business days
Form 10-Q quarterly financial report 40–45 days post quarter
Form 10-K annual report and audited statements 60–90 days year-end
Form S-1 registration for securities offering filing precedes offering

Security and Compliance Features to Protect Filing Data

In-transit Encryption: TLS 1.2/1.3
At-rest Encryption: AES-256 data encryption
Third-party Audit: SOC 2 Type II
Regulatory Standards: ISO 27001 certified
Healthcare Compliance: HIPAA — BAA required
FDA / Records: 21 CFR Part 11 support available

eSignature Pricing and Feature Comparison for SEC Filing Workflows

Compare baseline plans and core capabilities relevant to SEC filing workflows; signNow appears first for platform-level reference when assessing cost and compliance.

signNow DocuSign Adobe Sign PandaDoc HelloSign
Starting Price $8/user/mo $15/user/mo $14/user/mo $19/user/mo $15/user/mo
Free Trial 7-day free trial Varies by vendor Varies by vendor Varies by vendor Varies by vendor
Bulk Send Yes Yes Yes Yes No
Audit Trail Yes Yes Yes Yes Yes
HIPAA Compliant Yes Yes Yes No No

Frequently Asked Questions About SEC Filing and eSignatures

Answers address common uncertainties on authority to sign, e-sign legality, platform compliance, and EDGAR submission checks.


Need help? Contact support

be ready to get more
Join over 28 million airSlate SignNow users